 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...108109110111112113114115116117118...235236» |
- racemetyrosine (SM-88) / Tyme
Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_838;
P2/3, P3
Of note, for the small subset of pts treated in the second line, the mOS and mPFS were on par with results achieved in other published randomized PhIII second-line trials for mPDAC. Moreover, SM-88 Regimen exhibited far fewer Grade 3 and 4 AEs than other commonly used cytotoxic regimens in the second line.
- Graspa (eryaspase) / ERYtech
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update. (In-Person Only | Level 1, West Hall; Poster Board - J9) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_835;
P1, P3
The MTD has been declared with 5-FU 2400 mg/2, Oxaliplatin 85 mg/2, Irinotecan 150 mg/m2, and Eryaspase 100 units/kg. We plan to expand enrollment to further look at efficacy and are in the process of designing a larger randomized study in the first line setting pending results from the Trybeca-1 trial.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with ablative 5-fraction stereotactic magnetic resonance image-guided adaptive radiation therapy (SMART). (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_825;
Ablative 5-fraction SMART is associated with encouraging long-term LC and OS among elderly patients with PDAC. This novel treatment strategy is noninvasive, does not require anesthesia, is remarkably well tolerated among patients with advanced age despite the high prescription dose, and therefore should be strongly considered especially among older patients who have limited treatment options.
- Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience. (In-Person Only | Level 1, West Hall; Poster Board - H5) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_822;
In our small cohort study, more patients who received GTX+RT achieved R0 resection and N0 status as compared to FFX+RT. No difference in survival was detected but this may be due to inadequate power or choice of subsequent therapies.
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_817;
P2
Treatment was given as follows: Day 1 - Cyclophosphamide 200mg/m2 IV (All Arms), Nivolumab 480mg IV (Arms B, C), Urelumab 8mg IV (Arm C); Day 2 – GVAX ID (All Arms)...SOC regimes included (m)FOLFIRINOX, Gem +/- Cap/NAB-Paclitaxel... Despite a small sample size, combining GVAX with dual immune-targeting of PD-1 blockade and CD137 agonism was safe and may enhance DFS in rPDA pts treated in the perioperative and post-adjuvant settings.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_814;
In PDAC patients who underwent surgery following neoadjuvant mFOLFIRINOX, ACT may be associated with improved survival outcomes. Its benefit was not affected by the LN status and ACT regimens.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Resource utilization and total cost of care among Medicare advantage patients with metastatic pancreatic cancer receiving NCCN category 1 preferred regimens. (In-Person Only | Level 1, West Hall; Poster Board - F2) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_803;
Limitations: Analysis of different populations or time periods may yield different results. Our study used claims data and not electronic health records (EHRs), so we could not control for clinical covariates.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Optimal preoperative multidisciplinary treatment in borderline resectable pancreatic cancer: Results of a dual-center study. (In-Person Only | Level 1, West Hall; Poster Board - F1) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_802;
These findings suggest that prognosis may be improved by maintaining good nutritional status during preoperative treatment, not by the length of preoperative treatment. In addition, surgery after normalization of tumor markers levels by preoperative treatment contributes to the prolongation of survival.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Cancer Commons’ virtual tumor board program: A patient-centric advisory panel and real-world data registry. (In-Person Only | Level 1, West Hall; Poster Board - E9) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_800;
P=N/A
Early data indicate successes in identifying treatment and clinical trial opportunities. Future steps include streamlining communication with primary oncologists and enhancing access to treatments.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Unraveling the oligometastatic phenotype and its association with pancreatic cancer survival. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_789;
In this study, we propose an anatomically-based definition of oligometastatic disease for stage IV PDAC patients. Our data showed that patients with ≤5 isolated liver/lung metastases have a more favorable prognosis and may benefit from early consideration of multimodal therapy intensification.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_782;
P=N/A
We are the first to demonstrate the feasibility of plasma metabolomics in a prospective cohort of advanced PC pts on enteral feeding as their primary source of nutrition. Metabolic signatures unique to FOLFIRINOX or gemcitabine/nab-paclitaxel may be predictive of response and warrant further study.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_778;
Eighteen were treatment-naïve, 14 received FOLFIRINOX followed by radiotherapy with 5-FU or capecitabine (CRT), and 5 were subjected to CRT combined with losartan on protocol (CRTL)... Our work provides a high-resolution molecular framework for understanding the inter- and intra-tumoral heterogeneity of pancreatic cancer, spatial organization into discrete multicellular communities, and treatment-associated reprogramming as a blueprint for exploring novel therapeutic strategies tailored to residual disease.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Association of pancreatic adenocarcinoma location (head/body/tail) with DDR mutation status and response to platinum-based therapy. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_776;
DDR pathway alterations are known predictors of increased benefit from platinums and these real-world insights preliminarily suggest that DDR mutations are more common in BT vs. H. Prospective studies may be warranted to confirm the hypothesis-generating findings that platinum-based regimens should be prioritized in patients with BT tumors while underscoring the importance of routine NGS testing in both BT and H tumors given the prevalence of DDR pathway alterations on both sides of the pancreas.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka, elraglusib (9-ING-41) / Actuate Therap
Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC). (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_772;
P1/2
Based on efficacy data to date, including confirmed CRs, we have commenced a randomized phase 2 study, evaluating 9-ING-41 plus GnP vs Gn P alone. Enrollment to the randomized study is now open (NCT03678883).
- Opdivo (nivolumab) / Ono Pharma, BMS
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_766;
Nivolumab in combination with modified FOLFIRINOX had a manageable safety profile in patients with metastatic pancreatic cancer. Additional work is needed to determine the population who can benefit from the combination.
- leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_765;
P2
In addition, quality of life can be maintained during the treatment. GSL could be a treatment of choice for elderly patients with locally advanced or metastatic pancreatic cancer.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Early-onset pancreatic cancer: Defining contemporary presentation, treatment, and outcomes in the under 50 age group using real-world data. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_762;
EOPC are more likely to receive neoadjuvant chemotherapy and undergo resection when presenting with borderline resectable disease. EOPC receive more treatment and have superior OS, with RFS/PFS1 not statistically different to LOPC.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_761;
EOPC receive more treatment and have superior OS, with RFS/PFS1 not statistically different to LOPC. In routinely treated unselected patients, Gem-Nab is likely more costly and less effective than FOLFIRINOX and therefore, not considered cost-effective at any commonly accepted willingness-to-pay threshold.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the CISPD-4 study). (In-Person Only | Level 1, West Hall; Poster Board - M6) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_746;
P3
Modified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported.
- Tyvyt (sintilimab) / Eli Lilly
Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_742;
P3
Toxicity was manageable. These data suggest that combined PD-1 blockade may expand the benefit of chemotherapy in PDAC.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? (Pubmed Central) - Jan 7, 2022
FA with 15 mg fixed dose as compared to 0.1 mg/kg of FA was associated with similar primary remission rate, relapse or death among low-risk GTN treated with 8-day MTX. This regimen is highly practical, reduces visits to health facilities, appears equally safe and may be preferable with the 8-day MTX regimen in the treatment of low-risk GTN.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. (Pubmed Central) - Jan 7, 2022
In BRPC and LAPC, the KRAS G12V mutation was associated with better TRG following chemotherapy and SBRT. Additionally, NOTCH1/2 mutations were associated with worse overall survival, distant metastasis-free survival, and progression-free survival.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
A multi-omics approach to dissect the impact of the cancer secretome during pancreatic cancer progression. () - Jan 7, 2022 - Abstract #LCC2022LCC_160;
We will investigate if pharmacological and genetic inhibition of these proteins can reduce tumour burden and metastasis ± standard-of-care chemotherapies, Gemcitabine/Abraxane and FOLFIRINOX...Therefore, this robust assessment across multiple platforms identifies significant aberrantly secreted proteins in metastatic pancreatic cancer cells, of which several are associated with two common features of PDAC pathological mechanisms: extracellular matrix remodelling and reprogrammed metabolism. Ongoing work involves in vivo inhibition by repurposing FDA-approved drugs ± chemotherapies to investigate the impact of the cancer secretome on tumour progression in PDAC.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Improved prognosis of pancreatic cancer patients with peritoneal metastasis. (Pubmed Central) - Jan 6, 2022
Ongoing work involves in vivo inhibition by repurposing FDA-approved drugs ± chemotherapies to investigate the impact of the cancer secretome on tumour progression in PDAC. The prognosis of PC with peritoneal metastasis has significantly improved over time with the advent of GnP and mFFX.
- || oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Clinical, Journal, Monotherapy: Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II-III elderly colon cancer patients. (Pubmed Central) - Jan 6, 2022
The prognosis of PC with peritoneal metastasis has significantly improved over time with the advent of GnP and mFFX. Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer.
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2/3 trial: FROST: Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer (clinicaltrials.gov) - Jan 6, 2022
P2/3, N=308, Recruiting, Sponsor: Chungnam National University Hospital
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Circulating tumor DNA: I would switch to 2nd line chemo, like FOLFOX in the ex, and check ctDNA. Resistance alterations in ctDNA can confirm response to BRAF rx and guide retreatment (as you need resistance to clear). I don’t know of novel BRAF inhibitor trials enrolling acq res CRC unfortunately . (Twitter) - Jan 5, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: #CRCSM docs: for pts who progress on BREAKWATER [chemo + targeted arm], what are you advising for 2L? Eg if they had FOLFIRI + doublet, is FOLFOX preferable to more targeted tx? Can ctDNA inform decision? @VanMorrisMD @skopetz @GIcancerDoc @CathyEngMD @RonaYaeger @DocDustyD (Twitter) - Jan 5, 2022
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial completion date, Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jan 5, 2022
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer. Trial completion date: Dec 2021 --> Sep 2024 | Trial primary completion date: Dec 2021 --> Sep 2024
- |||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New trial: Resection Observatory (clinicaltrials.gov) - Jan 4, 2022
P=N/A, N=140, Active, not recruiting, Sponsor: Sanofi
- || cisplatin / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
Clinical, Journal: Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. (Pubmed Central) - Jan 4, 2022
Trial completion date: Dec 2021 --> Sep 2024 | Trial primary completion date: Dec 2021 --> Sep 2024 FOLFIRINOX is an option for the first-line treatment of patients with pancreatic cancer and good performance status.
- || irinotecan / Generic mfg.
Retrospective data, Review, Journal: Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature. (Pubmed Central) - Jan 4, 2022
Gemcitabine monotherapy seems without substantial activity in pACC. Whenever possible, patients with pACC should be screened for targetable mutations.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Combination therapy: Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. (Pubmed Central) - Jan 4, 2022
P3
However, the overall survival advantage, fewer adverse effects, and better health-related QOL associated with sequential bevacizumab administration might provide the basis for exploring antiangiogenic combination treatments with innovative perspectives. EudraCT Identifier: 2011-004997-27; ClinicalTrials.gov Identifier: NCT01718873.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P2 data, Journal, PD(L)-1 Biomarker: FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. (Pubmed Central) - Jan 4, 2022
P2
The safety run-in analysis of NIVACOR trial reassured using co-administration of FOLFOXIRI/bevacizumab and nivolumab was well tolerated with an acceptable toxicity profile. https://clinicaltrials.gov/, (NCT04072198).
- | Trial completion: PRODIGE-24: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 4, 2022
P3, N=493, Completed, Sponsor: UNICANCER
https://clinicaltrials.gov/, (NCT04072198). Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial completion: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Jan 4, 2022
P2, N=20, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed Suspended --> Completed
- | Enrollment open, Metastases: GRECCAR14: Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma (clinicaltrials.gov) - Jan 4, 2022
P2/3, N=430, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Suspended --> Completed Not yet recruiting --> Recruiting
- | Enrollment open, Metastases: GABRINOX2: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients (clinicaltrials.gov) - Jan 3, 2022
P2, N=210, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. (Pubmed Central) - Jan 1, 2022
Patients who respond to NAT likely have a favourable disease biology and will progress well following resection. It is these patients who should be selected for more aggressive upfront management, and those with resistant disease should be spared from high-risk surgery.
- || methotrexate IV / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia. (Pubmed Central) - Jan 1, 2022
There is no significant association between the clinical toxicity and MTX levels at the two points of measurement. An attempt to increase the MTX dose and/or to introduce a loading dose should be considered in subsequent ALL protocol as supported by further pharmacokinetic MTX studies in the Indonesian population.
- || Clinical, Journal: Organ Preservation in Rectal Cancer Patients Treated with Total Neoadjuvant Therapy. (Pubmed Central) - Jan 1, 2022
Approximately one-third of patients with stage II or III rectal cancer can benefit from a watch-and-wait approach with the aim of preserving the rectum if treated with induction-type total neoadjuvant therapy and followed by an experienced multidisciplinary team. See Video Abstract at http://links.lww.com/DCR/B688.
- || Xpovio (selinexor) / Karyopharm, Menarini
Clinical, Journal, Combination therapy: Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. (Pubmed Central) - Jan 1, 2022
P1
Registered 14 April 2015, https://clinicaltrials.gov/ct2/show/NCT02419495 ). Sponsor(s): Karyopharm Therapeutics.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Randomized Phase II Trial of Neoadjuvant Chemotherapy with Modified FOLFIRINOX Versus Modified FOLFIRINOX and PD-1 Antibody for Borderline Resectable and Locally Advanced Pancreatic Cancer (The CISPD-4 Study) (ePoster/eVideo) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_1413;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Controversial Benefit of 5-Fluorouracil/Leucovorin-Based Adjuvant Chemotherapy for Ampullary Cancer: A Propensity Score-Matched Analysis (ePoster/eVideo) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_1349;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Simultaneous Laparotomy Resection of Recurrent Colorectal Cancer and Liver Metastases Followed by FOLFIRI Adjuvant Chemotherapy: A Case Report (ePoster/eVideo) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_1005;
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Long-Term Survivors after FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Study (Gramercy) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_459;
Poor prognostic factors did not preclude the hope of actual 5 year survival. The TAPS consortium provides real-world outcomes for counseling patients and families at diagnosis.Table 1.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Repeated “Extreme” Liver Surgery in an Unresectable Patient: More than 10 Years of Follow-up (Rhinelander) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_443;
The patient came to our attention and received neoadjuvant therapy (10 cycles of FOLFIRI+cetuximab), then followed by a PSH consisting in a bisegmentectomy of S1-S4 with middle hepatic vein (MHV) preservation...Four cycles of “adjuvant” capecitabine were administered. In case of favorable tumor biology repeated “extreme” PSHs are feasible and positively affect the survival.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Robotic Distal Spleno-Pancreatectomy for Locally Advance Pancreatic Cancer: Difficult Access to the Celiac Trunk (Nassau) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_121;
Preoperative neoadjuvant chemotherapy with FOLFIRINOX with partial response...Uneventful postoperative course. At 6 months follow-up the patient remains well with no evidence of recurrent disease.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Modified Appleby Procedure with Left Gastric Artery Preservation and Superior Mesenteric Artery Divestment for Locally Advanced Pancreatic Body/Neck Tumour Post Neoadjuvant Treatment (Nassau) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_120;
Modified Appleby Procedure with left gastric artery preservation and common hepatic artery reconstruction is a feasible approach in locally advanced pancreatic neck/body tumour post neoadjuvant treatment with good biochemical response and acceptable morbidity. Good chemotherapy agents like FOLFIRINOX and SBRT result in tumour shrinkage away from major vessels and making R0 resection possible is a major revolution.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
FOLFOXIRI PLUS BEVACIZUMAB (BEV) PLUS ATEZOLIZUMAB (ATEZO) VERSUS FOLFOXIRI PLUS BEV AS FIRST-LINE TREATMENT OF UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: RESULTS OF THE PHASE II RANDOMIZED ATEZOTRIBE STUDY BY GONO (AUDITORIUM [VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_287;
P2
While the magnitude of benefit is significantly higher in dMMR tumors, signals of efficacy are reported also in the pMMR subgroup. Translational analyses to identify predictive biomarkers are ongoing.